NCT06614270View on ClinicalTrials.gov

Anti-CD19 IL-10 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

NARecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 6, 2025

Primary Completion Date

January 6, 2026

Study Completion Date

January 6, 2027

Conditions
Systemic Sclerosis (SSc)ANCA Associated Vasculitis (AAV)Idiopathic Inflammatory Myopathy (IIM)Sjogren's SyndromeAntiphospholipid Syndrome
Interventions
DRUG

anti-CD19 CAR-NK cells

Patients will receive Fludarabine and Cyclophosphamide for conditioning. Multiple doses of anti-CD19 CAR-NK cells will be infused on Day 0, 3, and 6.

Trial Locations (1)

310005

RECRUITING

the second affiliated hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER